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Introduction
Sumatriptan is a frequently applied anti-migraine treat-
ment, yet ≈20-30% migraineurs are nonresponders.
TRPV1 channels on trigeminal nerve endings release
CGRP during migraine attacks, while, supposedly, sti-
mulation of the presynaptic 5-HT(1B)/1D receptor by
sumatriptan inhibits this release. Capsaicin (CAP) stimu-
lates TRPV1 channels, causing CGRP-dependent vasodi-
latation, whereas electrical stimulation (ES) induces
vasodilation without direct TRPV1 activation.
Aim
To assess a possible biomarker for the efficacy of
sumatriptan.
Methods
We investigated the effect of sumatriptan on the rise of
dermal blood flow (DBF) of the forehead skin (innervated
by the trigeminal nerve) by CAP application (0.6 mg/ml)
and ES (0.2-1.0 mA) before and after subcutaneous pla-
cebo and sumatriptan in a randomized, double-blind, pla-
cebo controlled cross-over study, including healthy male
(n = 11, age ± SD: 29 ± 8 yrs) and female (n = 11, 32 ±
7 yrs) subjects.
Results
DBF responses to CAP (mean ± SEM: 313 ± 16 A.U.)
were significantly attenuated after sumatriptan (mean
decrease DBF: 82 ± 18 A.U., p < 0.001) but not after pla-
cebo (mean decrease DBF: 21 ± 12 A.U., p = 0.1026),
whereas DBF responses to ES were not affected by suma-
triptan or placebo. Sumatriptan, but not placebo,
increased blood pressure by 6 ± 2/11±2 mmHg, p <
0.001. In 23% of the subjects, sumatriptan did not attenu-
ate the DBF response.
Conclusions
Sumatriptan may inhibit the release of CGRP via the
stimulation of the presynaptic 5-HT(1B)/1D receptor
and/or by a direct effect on TRPV1 channels. ES appears
to be a nonspecific stimulus, most likely releasing other
neuropeptides besides CGRP. Future studies should
indicate whether nonresponse in our model correlates
with clinical nonresponse to sumatriptan.
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